Rituximab versus cyclophosphamide for ANCA-associated vasculitis (Q35109118)

6 August 2017

title

Rituximab versus cyclophosphamide for ANCA-associated vasculitis (English)

1 reference

6 August 2017

1 reference

Cees G M Kallenberg

1 reference

6 August 2017

Vicki Seyfert-Margolis

object named as

Vicki Seyfert-Margolis

1 reference

6 August 2017

E William St Clair

1 reference

6 August 2017

Carol A Langford

1 reference

6 August 2017

Paul A Monach

1 reference

6 August 2017

Coen Stegeman

1 reference

6 August 2017

Gary S Hoffman

1 reference

6 August 2017

Peter A Merkel

1 reference

6 August 2017

Ulrich Specks

1 reference

6 August 2017

John H Stone

1 reference

6 August 2017

Robert Spiera

1 reference

6 August 2017

Nadia K Tchao

1 reference

6 August 2017

Linna Ding

1 reference

6 August 2017

Steven R Ytterberg

1 reference

6 August 2017

Philip Seo

1 reference

6 August 2017

Anthony Turkiewicz

1 reference

6 August 2017

Lisa Webber

1 reference

6 August 2017

Lourdes P Sejismundo

1 reference

6 August 2017

Kathleen Mieras

1 reference

6 August 2017

David Weitzenkamp

1 reference

6 August 2017

David Ikle

1 reference

6 August 2017

Mark Mueller

1 reference

6 August 2017

Paul Brunetta

1 reference

6 August 2017

Nancy B Allen

1 reference

6 August 2017

Fernando C Fervenza

1 reference

6 August 2017

Duvuru Geetha

1 reference

6 August 2017

Karina A Keogh

1 reference

6 August 2017

Eugene Y Kissin

1 reference

6 August 2017

Tobias Peikert

1 reference

6 August 2017

RAVE-ITN Research Group

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

The New England Journal of Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

363

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

221-232

1 reference

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Etanercept plus standard therapy for Wegener's granulomatosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

The mechanisms of action of rituximab in the elimination of tumor cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Cyclophosphamide Therapy in Wegener's Granulomatosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Wegener's granulomatosis: studies in eighteen patients and a review of the literature

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Statistics in medicine--reporting of subgroup analyses in clinical trials.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

Wegener Granulomatosis: An Analysis of 158 Patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137658

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis

27 September 2018

1 reference

12 December 2020

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)

1 reference

12 December 2020

Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation

1 reference

12 December 2020

Suppression of human B lymphocyte function by cyclophosphamide

1 reference

12 December 2020

Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides

1 reference

12 December 2020

Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients

1 reference

12 December 2020

Differential B- and T-cell activation in Wegener's granulomatosis

1 reference

12 December 2020

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0909905

1 reference

6 August 2017

1 reference

6 August 2017

1 reference